An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel Biotechnology Fund (GIBF) that creates added value for Israeli, European and American companies looking to expand in China.
Kamari Pharma was established at the end of 2018 by the leading Israeli based biotechnology funds Pontifax and Arkin Bioholdings.
Prior to the current funding, $16 million had been invested in Kamari Pharma. The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3.
Kamari Pharma successfully completed the pre-clinical development of its first drug and is currently running clinical trials in patients in leading medical centers in Germany and Israel.
GIBF is a Chinese investment fund in the medical field. GIBF was established in 2016 in cooperation with the government of Guangzhou, the capital of South China, and is managed by the Israeli partners. The first fund, which raised about $100 million, made 12 investments in leading medical devices and digital health Israeli companies.
At the end of 2021, despite the severe Covid-19 restrictions in China, the fund announced the first closing of its second fund, which is planned to be about $300 million. GIBF2 focuses on Western biotechnology companies, which develop innovative drugs in phase 2/3 of clinical trials.
Shlomo Noy said: “We are particularly proud of joining forces with leading figures such as Pontifax, Arkin Bioholdings and Professor Aviezer. Our first fund helped 12 Israeli life sciences companies to establish subsidiaries in China and invested in those subsidiaries.
“These significant investments were made while keeping the control of the subsidiaries in the hands of the Israeli companies and fully protecting their IP. Our mutual goal is to develop innovative activity in China and to build value in this major market, which foreign companies typically leave in the hands of local partners.”
Kamari Pharma’s clinical programs
David Aviezer added: “We are glad with the cooperation and the significant investment by GIBF, which will allow us to continue promoting our clinical programs.
“The establishment of our subsidiary in China and the investment by GIBF will allow us to expand and accelerate our clinical trials by collaborating with the leading hospitals in China and allowing us to treat their significant patient population.
“This will also enable us to quickly and directly address the significant Chinese patient market, which is characterized by a large number of patients with these diseases.”